Active Ingredient: Insulin aspart
Insulin aspart is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
0.5 - 1 [iU] per kg of body weight
From 0.167 To 0.333 [iU] per kg of body weight 3 time(s) per day every day
The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
Insulin aspart dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.
Moreover insulin aspart can be used for continuous subcutaneous insulin infusion (CSII) in pump systems.
Insulin aspart vial can also be used if intravenous administration of insulin aspart, by physicians or other healthcare staff, is applicable.
Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.
The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50-70% of this requirement may be provided by insulin aspart and the remainder by intermediate-acting or long-acting insulin.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.
Insulin aspart is administered subcutaneously by injection in the abdominal wall, the thigh, the upper arm, the deltoid region or the gluteal region. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy. Subcutaneous injection in the abdominal wall ensures a faster absorption than other injection sites. Compared to soluble human insulin the faster onset of action of insulin aspart is maintained regardless of the injection site. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.
Due to the faster onset of action, insulin aspart should generally be given immediately before a meal. When necessary insulin aspart can be given soon after a meal.
Intravenous
0.5 - 1 [iU] per kg of body weight
From 0.5 To 1 [iU] per kg of body weight once every day
The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
Insulin aspart dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.
Moreover insulin aspart can be used for continuous subcutaneous insulin infusion (CSII) in pump systems.
Insulin aspart vial can also be used if intravenous administration of insulin aspart, by physicians or other healthcare staff, is applicable.
Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.
The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50-70% of this requirement may be provided by insulin aspart and the remainder by intermediate-acting or long-acting insulin.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.
If necessary, insulin aspart can be administered intravenously which should be carried out by physicians or other healthcare staff.
For intravenous use, infusion systems with insulin aspart 100 units/ml at concentrations from 0.05 unit/ml to 1.0 unit/ml insulin aspart in the infusion fluids 0.9% sodium chloride, 5% dextrose or 10% dextrose including 40 mmol/l potassium chloride using polypropylene infusion bags, are stable at room temperature for 24 hours.
Although stable over time, a certain amount of insulin will be initially adsorbed to the material of the infusion bag. Monitoring of blood glucose is necessary during insulin infusion.
Due to the faster onset of action, insulin aspart should generally be given immediately before a meal. When necessary insulin aspart can be given soon after a meal.
Subcutaneous
0.5 - 1 [iU] per kg of body weight
From 0.5 To 1 [iU] per kg of body weight once every day
The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
Insulin aspart dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.
Moreover insulin aspart can be used for continuous subcutaneous insulin infusion (CSII) in pump systems.
Insulin aspart vial can also be used if intravenous administration of insulin aspart, by physicians or other healthcare staff, is applicable.
Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.
The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50-70% of this requirement may be provided by insulin aspart and the remainder by intermediate-acting or long-acting insulin.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.
Insulin aspart may be used for CSII in pump systems suitable for insulin infusion. CSII should be administered in the abdominal wall. Infusion sites should be rotated.
When used with an insulin infusion pump, insulin aspart should not be mixed with any other insulin medicinal products.
Patients using CSII should be comprehensively instructed in the use of the pump system and use the correct reservoir and tubing for the pump. The infusion set (tubing and cannula) should be changed in accordance with the instructions in the product information supplied with the infusion set.
Patients administering NovoRapid by CSII must have an alternative insulin delivery method available in case of pump system failure.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
